Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | AKT1 | P31749 | 13/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | AKT2 | P31751 | 2/20 | 0.55 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.55 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776488 | 0.88 | MAPT (0.58) | MEN1KMT2AAKT1MAPTTP53 | |
| SCHEMBL4772342 | 0.88 | POLB (0.62) | AKT1MAPTTP53AKT2AKT3 | |
| SCHEMBL4773309 | 0.87 | AKT1 (0.57) | MEN1KMT2AAKT1MAPTTP53 | |
| Hydrochloric Acid SCHEMBL6980746 | 0.86 | POLB (0.61) | AKT1MAPTTP53AKT2AKT3 | |
| SCHEMBL4795185 | 0.86 | DPP4 (0.60) | MEN1KMT2AAKT1MAPTTP53 | |
| SCHEMBL4770054 | 0.85 | AKT1 (0.57) | AKT1TP53AKT2AKT3AKT1S1 | |
| SCHEMBL4778450 | 0.84 | HDAC8 (0.58) | MEN1KMT2AAKT1HSP90AA1AKT2 | |
| SCHEMBL4778157 | 0.82 | AKT1 (0.56) | MEN1KMT2AAKT1AKT1S1 | |
| SCHEMBL4773516 | 0.81 | TP53 (0.59) | MEN1KMT2AAKT1MAPTTP53 | |
| SCHEMBL4776886 | 0.80 | AKT1 (0.56) | AKT1MAPTTP53AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | claimed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | claimed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | MEN1 1807/4885KMT2A 41/4885AKT1 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.